TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02057471
Drug: Intravenous ferric carboxymaltose
Normalized name: Ferric Carboxymaltose
DrugBank: Ferric carboxymaltose (DB08917)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 1 gram intravenous ferric carboxymaltose (FERINJECT) will be administered to all patients within the study
Study: NCT04425733
Drug: MK-5475
Normalized name: vitamin MK 7
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475 administered at a dose of 180 µg or ≤360 µg QD via inhalation
Study: NCT04425733
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: MK-5475-matching placebo administered QD via inhalation
Study: NCT01391390
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 10mg/day, 12-week treatment
Study: NCT01391390
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10mg/day, 12-week treatment for TD
Study: NCT03689998
Drug: Melatonin
Normalized name: Melatonin
DrugBank: Melatonin (DB01065)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: topical application of melatonin
Study: NCT01516957
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo SC (subcutaneous)
Study: NCT03131336
Drug: PeproStat
Normalized name: Sus scrofa prostate preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: solution for local application
Study: NCT04139122
Drug: SJP-0132
Approvals — FDA: no, EMA: no, PMDA: no
Description: SJP-0132 is administered as an eye drop
Study: NCT04139122
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo is administered as an eye drop
Study: NCT02763852
Drug: BIA 3-202
Normalized name: Oatmeal 10 mg in 1 mL TOPICAL CREAM [BIA Eczema Relief]
Approvals — FDA: no, EMA: no, PMDA: no
Description: The study consisted of 5 treatment periods. Eligible subjects were admitted to the UFH on the morning of the day prior to receive the trial medication (dosing day) and remained in the unit for at least 30 h post-dose.~Subjects were to receive BIA 3-202 50 mg, 100 mg, 200 mg, 400 mg and placebo at 5 separate treatment periods.
Study: NCT02763852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo dose consisted of 5 tablets matching BIA 3-202 100 mg tablets; oral route.
Study: NCT02763852
Drug: Madopar® 125
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levodopa 100 mg/benserazide 25 mg capsules (Madopar® 125, marketed by Roche products Limited); oral route.
Study: NCT01042704
Drug: Prophylaxis
Normalized name: STONE PROPHYLAXIS
Approvals — FDA: no, EMA: no, PMDA: no
Description: All patients will receive prophylaxis with either an H-2 blocker or proton pump inhibitor (PPI) while on study medications. Suggested medications included ranitidine 150 mg PC BID or omeprazole 20 mg PO QD or equivalent.
Study: NCT03942198
Drug: Taodan Granules
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study: NCT03942198
Drug: Taodan Granules Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Put each bag of medicine in the same amount into the same container, pour about 50 ml of warm water, stir until the particles are basically dissolved, and then add appropriate amount of boiling water to dilute.
Study: NCT03623698
Drug: Nebulised hypertonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nebulised hypertonic saline used for a period of at least 12 months
Study: NCT00939276
Drug: Nepafenac ophthalmic suspension, 0.1% (NEVANAC®)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Study: NCT00939276
Drug: Nepafenac ophthalmic suspension vehicle
Normalized name: nepafenac Ophthalmic Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: One drop instilled in the study eye 3 times daily (morning, midafternoon, and bedtime) beginning the day before surgery, continuing on the day of surgery and through the first 90 days following surgery
Study: NCT00390533
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration (capsules)
Study: NCT00654407
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00654407
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02344680
Drug: Anti-HIV Agents
Normalized name: Anti Bac
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00295347
Drug: Spironolactone
Normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02556268
Drug: Antiretroviral protease inhibitor
Normalized name: Protease inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Any approved antiretroviral protease inhibitor such as atazanavir, darunavir, indinavir, ritonavir, and saquinavir ; consistent with the most recent prescribing information documents
Study: NCT01996826
Drug: Avastin® (bevacizumab)
Approvals — FDA: no, EMA: no, PMDA: no
Description: One time subconjunctival injection of 0.1 mL (2.5 mg) bevacizumab followed by topical treatment with 1% solution bevacizumab four times a day for four weeks.
Study: NCT01996826
Drug: 0.9% NaCl & Refresh Liquigel
Approvals — FDA: no, EMA: no, PMDA: no
Description: One-time subconjunctival injection of 0.1mL 0.9% NaCl followed by topical treatment with Refresh Liquigel four times a day for four weeks.
Study: NCT00695396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching volume 2 mLfor 48 weeks
Study: NCT00695396
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching volume 1 mL for 48 weeks
Study: NCT01545297
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The infusion begins at remifentanil 0.01-0.1 mcg/kg/min for 15 min, and then titrated to effect.
Study: NCT01312818
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Intrathecal Methotrexate at age based dose on day 1 (repeat on day 15 or 16 for CNS positive patients only)
Study: NCT01239771
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two subjects in each cohort will be given placebo.
Study: NCT01698931
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Before each main meal on three separate dosing visits separated by a wash-out period
Study: NCT03469479
Drug: FOLFOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Hepatic intra-arterial infusion via the tumor feeding arteries of Oxaliplatin , fluorouracil, and leucovorin
Study: NCT02256761
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02256761
Drug: BIRT 2584 XX - single dose
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00504439
Drug: Matching placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: SB-656933-AAA matching placebo tablets will be administered orally.
Study: NCT00504439
Drug: Simvastatin
Normalized name: Simvastatin
DrugBank: Simvastatin (DB00641)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Simvastatin will be provided as a 40 mg tablet.
Study: NCT03752112
Drug: Benzathine penicillin 2.4 million units
Approvals — FDA: no, EMA: no, PMDA: no
Description: Benzathine penicillin 2.4 million units: The investigators will include a contemporary arm of participants that will receive standard of care treatment with Benzathine penicillin 2.4 million units according to the Brazil national STI treatment guidelines. The investigators will use a ratio of 2 patients receiving cefixime to 1 patient receiving benzathine penicillin.This non-comparator arm of benzathine penicillin will be included to account for study population differences in terms of stage of disease, history of prior infection, experience of re-infection, experience of serofast state, or other co-factors that could impact serological response
Study: NCT01456130
Drug: Rapid-acting insulin secretagogue
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either of the following commercially available rapid-acting insulin secretagogues as prescribed by the Investigator: (i) Nateglinide: Dose: 30 mg tablet or 90 mg tablet (ii) Mitiglinide calcium hydrate: Dose: 5 mg tablet or 10 mg tablet
Study: NCT00004846
Drug: ABC/Gen-Probe/Chiron HIV-1/HCV 001
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00299260
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: normal saline
Study: NCT03302403
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide is used for lymphodepletion.
Study: NCT01316458
Drug: STI571 (Glivec®)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03012191
Drug: Gentamicin Sulfate
Normalized name: Gentamicin Sulfate
DrugBank: Gentamicin (DB00798)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Participants will be divided into three cohorts: topical gentamicin; Topical gentamicin with microneedle roller assistance; IV gentamicin. While the intervention is the same drug, the topical gentamicin is compounded into a 0.5% ointment and the IV gentamicin is prepared to 7.5 mg/kg body weight and administered over a 30 minutes.
Study: NCT01773967
Drug: LGG
Normalized name: LGG
Approvals — FDA: no, EMA: no, PMDA: no
Description: LGG 10\^10 cfu PO BID X 5 days
Study: NCT01531582
Drug: minocycline
Normalized name: Minocycline
DrugBank: Minocycline (DB01017)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: The participant's parent or guardian will be instructed to administer minocycline caplets by mouth twice daily. Parents or guardians will be instructed to avoid dairy products, antacids, or any vitamin preparation that contains any divalent or trivalent cations (e.g. Aluminum, Calcium, Magnesium, etc.) for one hour prior to, and two hours after study medication administration.
Study: NCT02954887
Drug: GWP42003-P
Normalized name: P
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clear, colorless to yellow solution containing cannabidiol dissolved in the excipients sesame oil and anhydrous ethanol with added sweetener (sucralose) and strawberry flavoring.
Study: NCT00754689
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral administration
Study: NCT02274961
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02240121
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo matching to rifaximin EIR tablets will be administered per the dose and schedule specified in the arm.
Study: NCT02389465
Drug: Escitalopram + Celecoxib
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive celecoxib in addition to escitalopram
Study: NCT01730612
Drug: TF2 - 68 Ga-IMP-288:
Approvals — FDA: no, EMA: no, PMDA: no
Description: ImmunoTEP
Study: NCT00815048
Drug: Atropine/Remifentanil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 20mcg/kg~Remifentanil 3mcg/kg
Study: NCT00815048
Drug: Fentanyl/Atropine/Succinylcholine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atropine 20mcg/kg~Fentanyl 2mcg/kg~Succinylcholine 2mg/kg
Study: NCT04156568
Drug: INH、RFT
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6INH 10mg/kg 3INH+RFT 15mg/kg
Study: NCT01393340
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00010075
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00010075
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00255216
Drug: Policosanol supplement (oral capsule) vs. placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00729443
Drug: AZD3241
Approvals — FDA: no, EMA: no, PMDA: no
Description: single oral dose
Study: NCT00729443
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01340664
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 placebo capsule taken orally twice daily with a meal for 18 weeks
Study: NCT02202967
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo contains lactose granules
Study: NCT00755963
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: maltodextrin
Study: NCT01230138
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo tablets
Study: NCT00153673
Drug: celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Celecoxib 200mg bd
Study: NCT02194946
Drug: CKD-related management
Approvals — FDA: no, EMA: no, PMDA: no
Description: Western medicine treatment for CKD are practised following KDIGO and KDOQI guidelines, to reach the recommended goals of nutrition, blood pressure, hemoglobulin, electrolytes, fluid control and acid-base balance.
Study: NCT05508178
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Norovirus vaccine (rNV-2v) vehicle without antigen
Study: NCT02100930
Drug: oral isotretinoin
Normalized name: Isotretinoin
DrugBank: Isotretinoin (DB00982)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT01619761
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Given IV
Study: NCT04556357
Drug: Norepinephrine
Normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: A maintenance dose of norepinephrine (0.05 μg/kg/min) infusion simultaneous with subarachnoid block
Study: NCT02843438
Drug: Anti-toxoplasmosis treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02843438
Drug: Anti-inflammatory treatments
Normalized name: Surpass Anti-Inflammatory
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00039039
Drug: chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00838812
Drug: application of the topic gel
Normalized name: The Itch Eraser Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Clindamycin Phosphate 1,2% and tretinoin 0,025% gel once daily at night 12 weeks.
Study: NCT01467466
Drug: IV isotonic saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: The investigators will administer 3 ml/kg of isotonic saline over 1 hour at an infusion rate of not less than 1 mL/kg per hour and not more than 3 mL/kg per hour prior to the angiographic procedure, 1-1.5ml/kg per hour during angiography, and 6 ml/kg of isotonic saline over 4 hours following the procedure at an infusion rate of not less than 1 mL/kg per hour and not more than 1.5 mL/kg per hour. Providers will retain discretion to administer larger volumes of isotonic saline (up to a maximum of 12 mL/kg) over durations of up to 12 hours pre and 12 hours post-procedure.
Study: NCT01467466
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A placebo study drug capsule will be administered orally 1 hour prior to angiography, 1 hour following the procedure, and then twice daily for the next 4 days.
Study: NCT04677543
Drug: Azithromycin
Normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Oral tablet
Study: NCT01320345
Drug: Inert lactose placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Insert lactose tablet matching active tablet administered once daily for 36 months.
Study: NCT01681667
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: ibuprofen liquid 400mg vs. ibuprofen tablet 400mg
Study: NCT00375466
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.9% sodium chloride 10 mg/kg, as a bolus injection before surgery followed by 1 mg/kg/h as an infusion during surgery
Study: NCT02592278
Drug: Control Group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice a day brush with fluoride toothpaste.
Study: NCT03388541
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: A continuous infusion of NaCL 0.9% will be started at 5mL/h while the patient is still in the operating room. The patient will be transferred to the intensive care unit with a sedative regimen based on propofol.
Study: NCT00190736
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02795299
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Methotrexate (MTX) to be administered once a week every week during the treatment period.
Study: NCT02795299
Drug: Folic Acid
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Acid folic (folate) 1mg to be administered once daily during the treatment period.
Study: NCT02795299
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mM acetate, 9% (w/v) sucrose, and 0.006% (w/v) polysorbate 20 at pH 5.2 ± 0.3
Study: NCT02288000
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: the placebo will be administered OS as of 10 mg- capsule one per day in the morning over 15 days.
Study: NCT00945373
Drug: calcium dobesilate
Normalized name: CALCIUM DOBESILATE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.5% gel
Study: NCT04271475
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participant will receive matching placebo tablets orally od.
Study: NCT00673231
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT01763333
Drug: BI 1026706 Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to BI 1026706
Study: NCT01973010
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen is an common analgesics which has been widely used in regular control of various pain symptom.
Study: NCT03497039
Drug: Diclofenac Diethylamine (DDEA) gel
Approvals — FDA: no, EMA: no, PMDA: no
Description: Diclofenac Diethylamine (DDEA) gel consists of 2.32% DDEA. DDEA gel will be applied twice a day for 7 days topically first and last dose by trained nurse (or designee) at study site and doses in between by a trained nurse at participant's home or other convenient location. Participants will be admitted on the day before the scheduled surgery (Day 7). The last dose of study treatment will be administered at the study site 12 hours (window -1/+3 hrs) prior to arthroplasty surgery.If surgery is delayed by up to 7 days dosing with DDEA gel twice daily can continue up to 14 days. If the surgery is delayed by more than 7 days, the participant should be withdrawn from the study.
Study: NCT04262479
Drug: recombinant human glutamic acid dehydrogenase (rhGAD65), formulated in aluminium hydrogel
Approvals — FDA: no, EMA: no, PMDA: no
Description: 3 intra-inguinal injections (into the lymph nodes) of GAD-alum one month apart. Supplier Diamyd Medical AB in Stockholm, Sweden
Study: NCT02462031
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 200mg, 400mg, 800mg
Study: NCT00459641
Drug: I-040302
Approvals — FDA: no, EMA: no, PMDA: no
Description: doses of up to 1 mg, 2 mg or 4 mg of TGplPTH1-34
Study: NCT02263950
Drug: Artemether
Normalized name: Artemether
DrugBank: Artemether (DB06697)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Artemether sublingual spray at 20mg per spray. Dose escalation study design as per protocol; in Phase 1, three dose levels will be given. The Phase 2 dose will be determined from the results of Phase 1. All patients will receive 4 cycles of dosing, 28 days per cycle.
Study: NCT01528787
Drug: AR-13324 Ophthalmic Solution 0.01%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to study eye, once daily (QD) in the morning (AM) for 7 days
Study: NCT01528787
Drug: AR-13324 Ophthalmic Solution 0.02%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to study eye, QD AM for 7 days
Study: NCT01528787
Drug: AR-13324 Ophthalmic Solution 0.04%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered to study eye, QD AM for 7 days
Study: NCT00849667
Drug: Taxane
Normalized name: Taxanes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Taxane (Paclitaxel or Docetaxel) IV infusion.
Study: NCT00851890
Drug: ABT-333
Normalized name: ABT-925
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 mg capsules
Study: NCT04171505
Drug: HPV vaccine
Normalized name: HPV vaccine 9-valent/PF 0.5 mL INTRAMUSC VIAL (ML)
Approvals — FDA: no, EMA: no, PMDA: no
Description: . Patients diagnosed with HSIL / CIN 2+ who met the inclusion criteria were submitted to cervical conization and subsequently enrolled in the study after signing the informed consent, approved by ethics commission.~We will take into account the date of administration of the first dose of vaccine. The types of vaccines administered can be: Bivalent vaccine (includes genotypes 16/18), Tetravalent (includeds genotypes 6, 11, 16 and 18) both funded in the region in different years, or not funded (Nonavalent vaccine; includes genotypes: 6, 11, 16, 18, 31, 33, 45, 52 and 58). To define the time of vaccination around the conization date, the administration of the first dose of vaccine will be taken into account.
Study: NCT02214901
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03954834
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered SC
Study: NCT03008070
Drug: IVA337
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1200mg
Study: NCT03008070
Drug: IVA337
Approvals — FDA: no, EMA: no, PMDA: no
Description: 800mg
Study: NCT03008070
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to match
Study: NCT00556439
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo abatacept infusions will be given monthly after random assignment at Month 3.
Study: NCT04368377
Drug: Acetylsalicylic acid
Normalized name: ACETYLSALICYLIC ACID
DrugBank: Acetylsalicylic acid (DB00945)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive acetylsalicylic acid 250 mg IV before starting tirofiban, and this will be continued at a dose of 75mg daily for 30 days.
Study: NCT04554732
Drug: Keratinocyte growth factor
Normalized name: Keratinocyte growth factor
Approvals — FDA: no, EMA: no, PMDA: no
Description: At the end of 4 cycles of chemotherapy, primary efficacy end point data will be collected. After 20 evaluable subjects if ≥ 4 responses were noted, part 2 of the study will be activated. The decision rule is based on the lower bound of a one-sided 95% confidence interval; at least 4 out of 20 patients with response results in a lower bound greater than 5% success. The proportion with success and the lower bound of a one-sided exact confidence interval will be computed.